ketamine-nightmares
Anaesthesia Primary Exam
Pharmacology SAQ
Analgesics
2000A15 Opioids - Respiratory Effects
2006A07 Naloxone
2007A03 Opioids - inter-individual variation
2007B03 Opioids - transition from IV to oral
2008B04 Ketamine - use in post-op analgesia
2010B01 Morphine vs oxycodone
2011A06 Remifentanil
2013B12 Alfentanil vs fentanyl
2013C08 Opioid metabolism - morphine, pethidine and codeine
2014A10 Morphine vs tramadol
2014A11 Aspirin overdose vs paracetamol overdose
2015A11 Morphine PCA vs fentanyl PCA
2016B12 Opioids - mechanism of analgesia
2017B12 Non-steroidal anti-inflammatory drugs
2017B15 Tramadol
2018A05 Opioids - therapeutic and adverse effects
2019A14 Tramadol - metabolism and excretion
2019B14 Paracetamol - role and toxicity
2020A09 Intrathecal opioids
Cardiovascular Drugs
1999B12 Sodium nitroprusside
2001A15 Esmolol vs propranolol
2002B08 Vasopressin
2004A06 Glyceryl trinitrate
2006B01 Treatment of hypotension due to subarachnoid block
2006B07 Treatment of ventricular fibrillation
2007A08 Treatment of chronic LV failure
2008A08 Treatment of myocardial ischaemia
2012B05 Drugs acting on the renin-angiotensin system
2015A08 Treatment of intra-operative hypertension
2016A08 Treatment of hypertension in pregnancy
2016A09 Amiodarone
2017B07 Ephedrine vs noradrenaline
2018A08 Metoprolol
2018B10 Inotropes
Haemostasis drugs
2004A08 Unfractionated heparin - adverse effects
2008B07 Anti-platelets
2011B05 Protamine
2012B01 Warfarin
2014B08 Bridging from warfarin to low molecular weight heparins
2017A08 Unfractionated heparin vs low molecular weight heparins
2020A06 Warfarin reversal
Inhalational Anaesthetics
1999A14 Volatile anaesthetics - renal effects
2000A09 Volatile anaesthetics - cardiovascular effects
2001A12 Volatile anaesthetics - respiratory effects
2001B10 Nitrous oxide - adverse effects
2004A01 Isoflurane - CNS effects
2005B01 Isoflurane - metabolism
2009A01 Minimum alveolar concentration
2010A03 Desflurane - adverse effects
2011A07 Nitrous oxide - advantages and disadvantages
2012A02 Nitrous oxide - pharmacokinetics
2013C02 Xenon - advantages and disadvantages
2014B03 Malignant hyperthermia
2015A07 Sevoflurane - effects on muscle
2017B05 Inhalational anaesthetics - rate of onset
2018A06 Sevoflurane - rate of washout.htm
2019A09 Inhalational anaesthetics - wash-in curves
2019A10 Sevoflurane - effects on regional circulations
2019B04 Volatile anaesthetics - mechanism of hypnosis
2020A04 Sevoflurane vs nitrous oxide - cardiovascular effects
2020A07 Desflurane washout
Intravenous Anaesthetics
1999A16 Alpha 2 adrenoceptor agonist
2002A11 Thiopentone and ketamine - non-CNS effects
2002A16 Flumazenil
2003B06 Alpha 2 adrenoceptor agonists - and limitations of clonidine
2004B07 Propofol - inter-invididual variatation in elimination half life
2006B03 Intravenous induction agents - inter-individual variation
2007A04 Propofol TIVA vs ketamine TIVA
2008A03 Ideal sedative
2008B02 Propofol TIVA
2008B03 Clonidine
2009B02 Propofol - adverse effects
2012A07 Ketamine TIVA
2012B02 Propofol vs sevoflurane - kinetics, CVS, CNS effects
2017B14 Propofol - non-CNS effects
2018A07 Intravenous induction - dosing in youth, old age and shock
2018B11 Midazolam
2019A11 Propofol TCI
2020A13 Intravenous induction - rate of onset
Local Anaesthetics
2002A09 Local anaesthetic toxicity
2003A03 Local anaesthetics - mechanism of action
2004A03 Local anaesthetics - topical agents
2004B02 Ropivacaine
2005B03 Lignocaine - physicochemical characteristics
2007A02 Local anaesthetics - neuraxial pharmacokinetics
2010A01 Local anaesthetics - structure-activity relationships
2011A01 Local anaesthetic systemic toxicity - risk factors
2015A04 Local anaesthetics - nasal application
2016A06 Local anaesthetics - rate of onset
2017A12 Total spinal anaesthesia
2017B08 Local anaesthetics - rate of offset
2019A08 Local anaesthetic systemic toxicity - features
2019B09 Local anaesthetics - rate of onset and offset
2020B09 Topical local anaesthetic toxicity
Miscellaneous Drugs
2000A12 Oxytocin
2000A14 Ester drugs
2004B03 Anti-histamines
2005B07 Droperidol
2008A02 Diuretics
2008B06 Colloids
2009A04 Atropine vs glycopyrrolate
2009A07 Serotonergic drugs
2009B03 Anti-emetics and pro-emetics
2010A07 Drugs acting at the nicotinic cholinergic receptor
2010A08 Anti-depressants
2012A03 Anti-aspiration drugs
2013C01 Oral hypoglycaemics
2014A06 Bronchodilators
2014A13 Normal saline vs 4% albumin
2016B11 Gentamicin
2016B15 Anti-emetics
2018B13 Oxytocics and tocolytics
2019A13 Antibiotic chemoprophylaxis
2019B10 Effects of CSL infusion
2020A02 Povidone iodine vs alcoholic chlorhexidine
2020B12 Mannitol
Muscle Relaxants
2000B16 Atracurium vs cisatracurium
2004A02 Non-depolarising relaxants - rate of onset
2006B04 Suxamethonium vs rocuronium - rapid sequence induction
2007B06 Suxamethonium - mechanisms of phase 1 and phase 2 block
2009B05 Non-depolarising relaxants - inter-individual variation
2010B05 Reversal - anti-cholinesterases
2013C04 Relaxants - cardiovascular effects
2014A02 Non-depolarising relaxants - log dose response curve
2016A04 Non-depolarising relaxants - adverse effects
2016B10 Reversal - neostigmine
2018A12 Reversal - neostigmine vs sugammadex
2018B04 Suxamethonium vs rocuronium
2019A12 Non-depolarising relaxants - rate of offset
2019B01 Suxamethonium - adverse effects
2020A14 Neostigmine - adverse effects
Pharmaceutics
2003A04 Intravenous drug additives
2013C03 Isomerism
2020B08 Anaesthetics and the environment
Pharmacodynamics
2002B06 Tolerance and dependence - opioids
2004B01 Mechanisms of drug action
2012B03 Tolerance and tachyphylaxis
2015A05 Synergy - sevoflurane and fentanyl
2019B06 Synergy - propofol and remifentanil
2020B11 Dose-response curves - opioids
Pharmacokinetics
2001B09 Clearance
2002A10 Rate of offset after a drug infusion
2011B02 Compartment modelling
2012B13 Exponential functions
2013C05 Volume of distribution
2015B04 Half-life vs context-sensitive half-time
2017A04 CYP2D6
2018B14 Transdermal kinetics
2020B15 Pharmacokinetics of chronic kidney disease